• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芬兰林奇综合征家系突变携带者的死因。

Causes of death of mutation carriers in Finnish Lynch syndrome families.

机构信息

Department of Surgery, Jyväskylä Central Hospital, Jyväskylä, Finland.

出版信息

Fam Cancer. 2012 Sep;11(3):467-71. doi: 10.1007/s10689-012-9537-3.

DOI:10.1007/s10689-012-9537-3
PMID:22684865
Abstract

Lynch syndrome (LS) is an autosomal dominant cancer syndrome including increased life-long risk for colorectal (CRC) and endometrial (EC) cancer, but also for cancers of other types. The risk for CRC is up to 70-80 % and for EC up to 50-60 %. Due to screening and early diagnosing the mortality related to CRC and EC seems to be low. In spite of many studies on surveillance of mutation carriers, there is no comprehensive evaluation on causes of death in LS families. The disease history and cause of death of all the deceased, tested mutation carriers and their mutation negative relatives in the Finnish LS families (N = 179) was examined utilizing hospital records and relevant national registries. Out of 1069 mutation carriers 151 had succumbed; 97 (64 %) from cancer. Out of 1146 mutation-negative family 44 members had died; 11 (25 %) of them from cancer. In 12 (7.7 %) of the deceased mutation carriers no cancer had been diagnosed. The mean age of death from cancer was 63.2 years vs. 68.8 years from non-cancer causes. Only 7.9 % of the patients with CRC had died from CRC and 5 % of those with EC, respectively. 61 % of the cancer deaths were related to extra-colonic, extra-endometrial cancers. The cumulative overall and cancer specific death rates were significantly increased in Mut+ compared to Mut- family members. Even surveillance yields decrease in the life-long risk and mortality of the most common cancers CRC and EC in LS, almost all mutation carriers will contract with cancer, and two thirds of the deceased have died from cancer. This should be taken in account in genetic counseling. Mutation carriers should be encouraged to seek help for abnormal symptoms.

摘要

林奇综合征(LS)是一种常染色体显性遗传的癌症综合征,包括终生增加结直肠癌(CRC)和子宫内膜癌(EC)的风险,但也增加其他类型癌症的风险。CRC 的风险高达 70-80%,EC 高达 50-60%。由于筛查和早期诊断,CRC 和 EC 的死亡率似乎较低。尽管对突变携带者的监测进行了许多研究,但对 LS 家族中死亡原因尚未进行全面评估。利用医院记录和相关的国家登记处,检查了所有已故、经测试的突变携带者及其突变阴性亲属(芬兰 LS 家族,N=179)的病史和死因。在 1069 名突变携带者中,有 151 人死亡;其中 97 人(64%)死于癌症。在 1146 名突变阴性家族成员中,有 44 人死亡;其中 11 人(25%)死于癌症。在 12 名(7.7%)已故的突变携带者中,没有诊断出癌症。癌症相关死亡的平均年龄为 63.2 岁,而非癌症相关死亡的平均年龄为 68.8 岁。CRC 和 EC 患者的死亡人数分别仅占 CRC 和 EC 患者的 7.9%和 5%。61%的癌症死亡与结直肠外、子宫内膜外癌症有关。与 Mut-家族成员相比,Mut+家族成员的总体和癌症特异性死亡率均显著增加。即使监测使 LS 中最常见的 CRC 和 EC 癌症的终生风险和死亡率降低,几乎所有突变携带者都会患上癌症,三分之二的死者死于癌症。这在遗传咨询中应予以考虑。应鼓励突变携带者寻求异常症状的帮助。

相似文献

1
Causes of death of mutation carriers in Finnish Lynch syndrome families.芬兰林奇综合征家系突变携带者的死因。
Fam Cancer. 2012 Sep;11(3):467-71. doi: 10.1007/s10689-012-9537-3.
2
Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members.林奇综合征突变检测十年后:突变阳性和突变阴性家族成员的癌症发病率及预后
J Clin Oncol. 2009 Oct 1;27(28):4793-7. doi: 10.1200/JCO.2009.23.7784. Epub 2009 Aug 31.
3
Risks of Lynch syndrome cancers for MSH6 mutation carriers.MSH6 突变携带者的林奇综合征癌症风险。
J Natl Cancer Inst. 2010 Feb 3;102(3):193-201. doi: 10.1093/jnci/djp473. Epub 2009 Dec 22.
4
The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.林奇综合征患者发生结肠外、子宫内膜外癌症的风险。
Int J Cancer. 2008 Jul 15;123(2):444-449. doi: 10.1002/ijc.23508.
5
The contribution of Lynch syndrome to early onset malignancy in Ireland.林奇综合征在爱尔兰早发性恶性肿瘤中的作用。
BMC Cancer. 2021 May 26;21(1):617. doi: 10.1186/s12885-021-08263-z.
6
Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.遗传性子宫内膜癌患者中 BRCA 和 MMR 基因突变的流行情况。
Med Oncol. 2021 Jan 23;38(2):13. doi: 10.1007/s12032-021-01454-5.
7
Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry.DNA 错配修复基因突变携带者的癌症谱:来自基于医院的林奇综合征登记处的结果。
Fam Cancer. 2012 Sep;11(3):441-7. doi: 10.1007/s10689-012-9534-6.
8
Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma.遗传性非息肉病性结直肠癌相关的结肠癌女性患者的子宫内膜癌发病风险。
Int J Cancer. 2010 Dec 1;127(11):2678-84. doi: 10.1002/ijc.25501.
9
High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation.携带 MSH2 A636P 突变的阿什肯纳兹家族中结直肠癌和子宫内膜癌的风险很高。
Gastroenterology. 2011 Jun;140(7):1919-26. doi: 10.1053/j.gastro.2011.02.071. Epub 2011 Mar 16.
10
The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations.因种系PMS2突变导致的林奇综合征的临床表型。
Gastroenterology. 2008 Aug;135(2):419-28. doi: 10.1053/j.gastro.2008.04.026. Epub 2008 May 2.

引用本文的文献

1
Gynaecological cancer surveillance for women with Lynch syndrome: systematic review and cost-effectiveness evaluation.林奇综合征女性的妇科癌症监测:系统评价和成本效益评估。
Health Technol Assess. 2024 Aug;28(41):1-228. doi: 10.3310/VBXX6307.
2
Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.胃肠道恶性肿瘤:遗传与临床应用。
Cancer Treat Res. 2024;192:305-418. doi: 10.1007/978-3-031-61238-1_15.
3
Lynch syndrome: from detection to treatment.林奇综合征:从检测到治疗

本文引用的文献

1
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.遗传性结直肠癌携带者中阿司匹林对癌症风险的长期影响:来自 CAPP2 随机对照试验的分析。
Lancet. 2011 Dec 17;378(9809):2081-7. doi: 10.1016/S0140-6736(11)61049-0. Epub 2011 Oct 27.
2
Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery.错配修复基因突变携带者的结直肠重复癌风险:更广泛结肠手术的优势。
Gut. 2011 Jul;60(7):950-7. doi: 10.1136/gut.2010.228056. Epub 2010 Dec 30.
3
One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome.
Front Oncol. 2023 May 1;13:1166238. doi: 10.3389/fonc.2023.1166238. eCollection 2023.
4
The contribution of Lynch syndrome to early onset malignancy in Ireland.林奇综合征在爱尔兰早发性恶性肿瘤中的作用。
BMC Cancer. 2021 May 26;21(1):617. doi: 10.1186/s12885-021-08263-z.
5
Body Weight, Physical Activity, and Risk of Cancer in Lynch Syndrome.林奇综合征患者的体重、体力活动与癌症风险
Cancers (Basel). 2021 Apr 13;13(8):1849. doi: 10.3390/cancers13081849.
6
PMS2 germline mutation c.943C>T (p.Arg315*)-induced Lynch syndrome-associated ovarian cancer.PMS2 种系突变 c.943C>T(p.Arg315*) 导致的林奇综合征相关卵巢癌。
Mol Genet Genomic Med. 2019 Jun;7(6):e721. doi: 10.1002/mgg3.721. Epub 2019 May 5.
7
Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types.迈向林奇综合征基于基因和性别的风险评估;13种结直肠癌以外癌症类型的年龄特异性发病率
Br J Cancer. 2017 Nov 21;117(11):1702-1710. doi: 10.1038/bjc.2017.348. Epub 2017 Oct 24.
8
Cancer risk and survival in carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database.携带者的癌症风险和生存情况,按基因和性别分析,直至 75 岁:前瞻性 Lynch 综合征数据库报告。
Gut. 2018 Jul;67(7):1306-1316. doi: 10.1136/gutjnl-2017-314057. Epub 2017 Jul 28.
9
Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database.既往患癌的致病性错配修复(MMR)基因变异携带者后续发生癌症的发病率及生存率:来自前瞻性林奇综合征数据库的报告
Gut. 2017 Sep;66(9):1657-1664. doi: 10.1136/gutjnl-2016-311403. Epub 2016 Jun 3.
10
Practical issues related to uterine pathology: staging, frozen section, artifacts, and Lynch syndrome.与子宫病理学相关的实际问题:分期、冰冻切片、伪像和林奇综合征。
Mod Pathol. 2016 Jan;29 Suppl 1(Suppl 1):S59-77. doi: 10.1038/modpathol.2015.127.
1 至 2 年的监测间隔可降低林奇综合征家族结直肠癌的风险。
Gastroenterology. 2010 Jun;138(7):2300-6. doi: 10.1053/j.gastro.2010.02.053. Epub 2010 Mar 2.
4
Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia.子宫内膜肿瘤发生的分子分析:复杂性增生而非非典型增生的重要性。
Clin Cancer Res. 2009 Sep 15;15(18):5772-83. doi: 10.1158/1078-0432.CCR-09-0506. Epub 2009 Sep 1.
5
Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members.林奇综合征突变检测十年后:突变阳性和突变阴性家族成员的癌症发病率及预后
J Clin Oncol. 2009 Oct 1;27(28):4793-7. doi: 10.1200/JCO.2009.23.7784. Epub 2009 Aug 31.
6
The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.林奇综合征患者发生结肠外、子宫内膜外癌症的风险。
Int J Cancer. 2008 Jul 15;123(2):444-449. doi: 10.1002/ijc.23508.
7
Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome.林奇综合征结肠镜监测中结直肠肿瘤的发生
Gastroenterology. 2007 Oct;133(4):1093-8. doi: 10.1053/j.gastro.2007.08.019. Epub 2007 Aug 14.
8
Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors.解释与错配修复(MMR)缺陷型和MMR稳定型肿瘤相关的家族性结直肠癌风险。
Clin Cancer Res. 2007 Jan 1;13(1):356-61. doi: 10.1158/1078-0432.CCR-06-1256.
9
Compliance and Satisfaction with Long-Term Surveillance in Finnish HNPCC Families.芬兰遗传性非息肉病性结直肠癌(HNPCC)家系对长期监测的依从性和满意度
Fam Cancer. 2006;5(2):175-8. doi: 10.1007/s10689-005-5442-3.
10
Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.遗传性非息肉病性结直肠癌综合征的癌症风险:发病年龄较晚。
Gastroenterology. 2005 Aug;129(2):415-21. doi: 10.1016/j.gastro.2005.05.011.